SCYX vs CGBS Comparison

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Crown LNG Holdings Ltd is an LNG infrastructure company that seeks to provide natural gas liquefaction, storage, and re-gasification services. It focuses on enabling a stable and reliable supply of LNG to customers, especially in geographic areas where onshore or floating facilities may be difficult or less desirable as a result of harsh weather conditions, safety or environmental concerns, or cost. It specializes in the design and operation of offshore, all-weather LNG liquefication and re-gasification terminals, such as gravity-based structures. Through Its technologies and design, It believes it can deliver tailored LNG infrastructure suitable for energy-isolated locations, as well as provide critical LNG infrastructure to under-served markets around the world.